Shares of Immune Design Corp. (NASDAQ:IMDZ) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $14.75.

IMDZ has been the subject of a number of recent research reports. Zacks Investment Research upgraded Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. ValuEngine upgraded Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Royal Bank Of Canada initiated coverage on Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Wells Fargo & Company cut Immune Design Corp. from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th.

In other Immune Design Corp. news, Director Peter Svennilson purchased 2,681,000 shares of the stock in a transaction on Friday, October 27th. The stock was bought at an average price of $4.10 per share, for a total transaction of $10,992,100.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Leo Guthart purchased 2,439,000 shares of the stock in a transaction on Friday, October 27th. The stock was acquired at an average price of $4.10 per share, with a total value of $9,999,900.00. The disclosure for this purchase can be found here. Insiders acquired a total of 5,250,000 shares of company stock valued at $21,649,900 in the last 90 days. 20.70% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. grew its holdings in Immune Design Corp. by 4.2% in the 3rd quarter. Victory Capital Management Inc. now owns 2,060,234 shares of the biotechnology company’s stock valued at $21,324,000 after buying an additional 82,670 shares during the period. Franklin Resources Inc. grew its holdings in Immune Design Corp. by 2.7% in the 2nd quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock valued at $7,412,000 after buying an additional 20,000 shares during the period. JPMorgan Chase & Co. grew its holdings in Immune Design Corp. by 118.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock valued at $5,175,000 after buying an additional 288,009 shares during the period. Vanguard Group Inc. grew its holdings in Immune Design Corp. by 37.9% in the 2nd quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock valued at $5,118,000 after buying an additional 144,408 shares during the period. Finally, FMR LLC grew its holdings in Immune Design Corp. by 0.4% in the 1st quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after buying an additional 1,699 shares during the period. Institutional investors own 51.44% of the company’s stock.

WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/immune-design-corp-imdz-receives-average-recommendation-of-buy-from-analysts.html.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.62 million. Immune Design Corp. had a negative return on equity of 64.22% and a negative net margin of 619.62%.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.